ACNP - Italian Periodicals Catalogue

AAAAAA

ITA
ENG

Results: 1-25 | 26-38

Results: 1-25/38

Structure and expression of the mouse cardiac calsequestrin gene

Authors: Frank, KF Mesnard-Rouiller, L Chu, GX Young, KB Zhao, W Haghighi, K Sato, Y Kranias, EG

Citation: Kf. Frank et al., Structure and expression of the mouse cardiac calsequestrin gene, BAS R CARD, 96(6), 2001, pp. 636-644

Phospholamban regulation of bladder contractility: evidence from gene-altered mouse models

Authors: Nobe, K Sutliff, RL Kranias, EG Paul, RJ

Citation: K. Nobe et al., Phospholamban regulation of bladder contractility: evidence from gene-altered mouse models, J PHYSL LON, 535(3), 2001, pp. 867-878

Is myosin phosphatase regulated in vivo by inhibitor-1? Evidence from inhibitor-1 knockout mice

Authors: Carr, AN Sutliff, RL Weber, CS Allen, PB Greengard, P de Lanerolle, P Kranias, EG Paul, RJ

Citation: An. Carr et al., Is myosin phosphatase regulated in vivo by inhibitor-1? Evidence from inhibitor-1 knockout mice, J PHYSL LON, 534(2), 2001, pp. 357-366

Re-evaluation of heart failure in transgenic mice with impaired SR Ca2+ release

Authors: Sato, Y Schmidt, AG Kiriazis, H Hoit, BD Kranias, EG

Citation: Y. Sato et al., Re-evaluation of heart failure in transgenic mice with impaired SR Ca2+ release, J MOL CEL C, 33(9), 2001, pp. 1757-1759

Gender influences on sarcoplasmic reticulum Ca2+-handling in failing humanmyocardium

Authors: Dash, R Frank, KF Carr, AN Moravec, CS Kranias, EG

Citation: R. Dash et al., Gender influences on sarcoplasmic reticulum Ca2+-handling in failing humanmyocardium, J MOL CEL C, 33(7), 2001, pp. 1345-1353

The enhanced contractility of the phospholamban-deficient mouse heart persists with aging (vol 33, pg 1031, 2001)

Authors: Slack, JP Grupp, IL Dash, R Holder, D Schmidt, A Gerst, MJ Tamura, T Tilgmann, C James, PF Johnson, R Gerdes, AM Kranias, EG

Citation: Jp. Slack et al., The enhanced contractility of the phospholamban-deficient mouse heart persists with aging (vol 33, pg 1031, 2001), J MOL CEL C, 33(7), 2001, pp. 1387-1387

The enhanced contractility of the phospholamban-deficient mouse heart persists with aging

Authors: Slack, JP Grupp, IL Dash, R Holder, D Schmidt, A Gerst, MJ Tamura, T Tilgmann, C James, PF Johnson, R Gerdes, AM Kranias, EG

Citation: Jp. Slack et al., The enhanced contractility of the phospholamban-deficient mouse heart persists with aging, J MOL CEL C, 33(5), 2001, pp. 1031-1040

Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy

Authors: Freeman, K Lerman, I Kranias, EG Bohlmeyer, T Bristow, MR Lefkowitz, RJ Iaccarino, G Koch, WJ Leinwand, LA

Citation: K. Freeman et al., Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy, J CLIN INV, 107(8), 2001, pp. 967-974

Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure

Authors: Haghighi, K Schmidt, AG Hoit, B Brittsan, AG Yatani, A Lester, JW Zhai, J Kimura, Y Dorn, GW MacLennan, DH Kranias, EG

Citation: K. Haghighi et al., Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure, J BIOL CHEM, 276(26), 2001, pp. 24145-24152

Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation

Authors: Sato, Y Kiriazis, H Yatani, A Schmidt, AG Hahn, H Ferguson, DG Sako, H Mitarai, S Honda, R Mesnard-Rouiller, L Frank, KF Beyermann, B Wu, GY Fujimori, K Dorn, GW Kranias, EG

Citation: Y. Sato et al., Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation, J BIOL CHEM, 276(12), 2001, pp. 9392-9399

Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality

Authors: Dash, R Kadambi, VJ Schmidt, AG Tepe, NM Biniakiewicz, D Gerst, MJ Canning, AM Abraham, WT Hoit, BD Liggett, SB Lorenz, JN Dorn, GW Kranias, EG

Citation: R. Dash et al., Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality, CIRCULATION, 103(6), 2001, pp. 889-896

Phospholamban and cardiac contractility

Authors: Frank, K Kranias, EG

Citation: K. Frank et Eg. Kranias, Phospholamban and cardiac contractility, ANN MED, 32(8), 2000, pp. 572-578

Phosphorylation of phospholamban and troponin I in beta-adrenergic-inducedacceleration of cardiac relaxation

Authors: Li, L Desantiago, J Chu, GX Kranias, EG Bers, DM

Citation: L. Li et al., Phosphorylation of phospholamban and troponin I in beta-adrenergic-inducedacceleration of cardiac relaxation, AM J P-HEAR, 278(3), 2000, pp. H769-H779

Influence of sarcoplasmic reticulum calcium loading on mechanical and relaxation restitution

Authors: Hoit, BD Kadambi, VJ Tramuta, DA Ball, N Kranias, EG Walsh, RA

Citation: Bd. Hoit et al., Influence of sarcoplasmic reticulum calcium loading on mechanical and relaxation restitution, AM J P-HEAR, 278(3), 2000, pp. H958-H963

Phospholamban: a major determinant of the cardiac force-frequency relationship

Authors: Bluhm, WF Kranias, EG Dillmann, WH Meyer, M

Citation: Wf. Bluhm et al., Phospholamban: a major determinant of the cardiac force-frequency relationship, AM J P-HEAR, 278(1), 2000, pp. H249-H255

The enhanced contractility in phospholamban deficient mouse hearts is not associated with alterations in Ca2+-sensitivity or myosin ATPase-activity of the contractile proteins

Authors: Schwinger, RHG Brixius, K Savvidou-Zaroti, P Bolck, B Zobel, C Frank, K Kranias, EG Hoischen, S Erdmann, E

Citation: Rhg. Schwinger et al., The enhanced contractility in phospholamban deficient mouse hearts is not associated with alterations in Ca2+-sensitivity or myosin ATPase-activity of the contractile proteins, BAS R CARD, 95(1), 2000, pp. 12-18

Genetically engineered models with alterations in cardiac membrane calcium-handling proteins

Authors: Kiriazis, H Kranias, EG

Citation: H. Kiriazis et Eg. Kranias, Genetically engineered models with alterations in cardiac membrane calcium-handling proteins, ANN R PHYSL, 62, 2000, pp. 321-351

Commentary on the special topic section on the use of transgenic models

Authors: Kranias, EG

Citation: Eg. Kranias, Commentary on the special topic section on the use of transgenic models, ANN R PHYSL, 62, 2000, pp. 965-969

Cardiac-specific overexpression of calsequestrin results in left ventricular hypertrophy, depressed force-frequency relation and pulsus alternans in vivo

Authors: Schmidt, AG Kadambi, VJ Ball, N Sato, Y Walsh, RA Kranias, EG Hoit, BD

Citation: Ag. Schmidt et al., Cardiac-specific overexpression of calsequestrin results in left ventricular hypertrophy, depressed force-frequency relation and pulsus alternans in vivo, J MOL CEL C, 32(9), 2000, pp. 1735-1744

Influence of transgenic overexpression of phospholamban on postextrasystolic potentiation (vol 31, pg 2007, 1999)

Authors: Hoit, BD Tramuta, DA Kadambi, VJ Dash, R Ball, N Kranias, EG Walsh, RA

Citation: Bd. Hoit et al., Influence of transgenic overexpression of phospholamban on postextrasystolic potentiation (vol 31, pg 2007, 1999), J MOL CEL C, 32(2), 2000, pp. 341-341

Phospholamban and cardiac contractile function

Authors: Brittsan, AG Kranias, EG

Citation: Ag. Brittsan et Eg. Kranias, Phospholamban and cardiac contractile function, J MOL CEL C, 32(12), 2000, pp. 2131-2139

Cardiac-specific overexpression of calsequestrin results in left ventricular hypertrophy, depressed force-frequency relation and pulsus alternans in vivo (vol 32, pg 1735, 2000)

Authors: Schmidt, AG Kadambi, VJ Ball, N Sato, Y Walsh, RA Kranias, EG Hoit, BD

A single site (Ser(16)) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists

Authors: Chu, GX Lester, JW Young, KB Luo, WS Zhai, J Kranias, EG

Citation: Gx. Chu et al., A single site (Ser(16)) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists, J BIOL CHEM, 275(49), 2000, pp. 38938-38943

The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility

Authors: Zvaritch, E Backx, PH Jirik, F Kimura, Y de Leon, S Schmidt, AG Hoit, BD Lester, JW Kranias, EG MacLennan, DH

Citation: E. Zvaritch et al., The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility, J BIOL CHEM, 275(20), 2000, pp. 14985-14991

Maximal inhibition of SERCA2 Ca2+ affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban

Authors: Brittsan, AG Carr, AN Schmidt, AG Kranias, EG

Citation: Ag. Brittsan et al., Maximal inhibition of SERCA2 Ca2+ affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban, J BIOL CHEM, 275(16), 2000, pp. 12129-12135

Risultati: 1-25 | 26-38